BPC July 28 update

Infinity INFI +61% WF analyst upgrade

Price and Volume Movers

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) rose 61% to close with a price of $2.45 on news that Wells Fargo had upgraded its analyst rating of the company from equal-weight to overweight, with a new price target of $14.00 vs. $4.00 prior.

I-Mab (NASDAQ:IMAB) announced that an Investigational New Drug (IND) application for the initiation of a Phase 2 clinical trial of efineptakin alfa in combination with anti-PD-1 antibody in patients with advanced solid tumors, including triple-negative breast cancer and head and neck cancers, has been accepted by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA). The stock price rose 22% to $73.76 for the day.

Alzamend Neuro, Inc. (NASDAQ:ALZN) announced the FDA has accepted its Investigational New Drug (IND) application for a Phase 1 trial of AL001, used to treat patients with severe cognitive impairment associated with Alzheimer's disease. The stock rose 18% to $5.22 on the news.

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) announced that the FDA has cleared the company’s Investigational New Drug (IND) applications for FPI-1966 and FPI-1967 for multiple tumor types, particularly head and neck and bladder cancers. The stock is currently up 12% in after hours trading with a price of $9.20.

-

Other major price movers (stocks priced > $1.00, volume > 50k listed on NASDAQ/NYSE):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:

ADVANCERS:

Aurinia Pharmaceuticals Inc. (AUPH): $14.24; +24%

Zai Lab Limited (ZLAB): $142.63; +23%

Pharvaris N.V. (PHVS): $17.12; +19%

Nymox Pharmaceutical Corporation (NYMX): $1.54; +18%

GeoVax Labs, Inc. (GOVX): $5.09; +17%

DECLINERS:

EyeGate Pharmaceuticals, Inc. (EYEG): $3.21; -15%

Tyme Technologies, Inc. (TYME): $1.22; -10%

NRx Pharmaceuticals, Inc. (NRXP): $16.25; -9%

ObsEva SA (OBSV): $2.63; -8%

Applied Molecular Transport Inc. (AMTI): $29.36; -8%

Pipeline updates below:

Pipeline Database Updates

Drug Price Stage Catalyst Market Cap

ABEO – Abeona Therapeutics Inc.
ABO-101 (Transpher B)
Sanfilippo syndrome type B (MPS IIIB)

$1.20
-0.04  -3%
Phase 1/2 Phase 1/2 two-year neurocognitive data due 1H 2022.
$121.5 million

ALXO – ALX Oncology Holdings Inc.
ALX148 and KEYTRUDA (pembrolizumab) - ASPEN-04
Head and Neck Squamous Cell Carcinoma

$77.81
-3.10  -4%
Phase 2 Phase 2 initiation of dosing announced July 28, 2021.
$3.1 billion

ALZN – Alzamend Neuro Inc.
AL001
Alzheimer’s disease

$2.60
-0.07  -3%
Phase 1 Phase 1 dosing initiated September 13, 2021.
$225.9 million

BPMC – Blueprint Medicines Corporation
BLU-222
CCNE-aberrant cancers

$106.00
+3.04  +3%
Phase 1 Phase 1 trial to be initiated 1H 2022.
$6.2 billion

FUSN – Fusion Pharmaceuticals Inc.
FPI-1966
Head and Neck and Bladder Cancers

$8.98
+0.04  +0%
Phase 1 Phase 1 trial to be initiated around the end of 2021, with interim data due around the end of 2022.
$386.3 million

GSK – GlaxoSmithKline PLC
COVID-19 (Medicago) vaccine
COVID-19 vaccine

$38.93
-0.18  -0%
Phase 3 Phase 3 data due 2H 2021.
$97.9 billion

KPTI – Karyopharm Therapeutics Inc.
XPOVIO (selinexor) and KEYTRUDA (pembrolizumab) - (XPORT-MEL-033)
Melanoma

$6.07
+0.27  +5%
Phase 2 Phase 2 initiation of dosing announced July 28, 2021.
$458.3 million

KPTI – Karyopharm Therapeutics Inc.
XPOVIO (selinexor) and JAKAFI (ruxolitinib) - (XPORT-MF-034)
Myelofibrosis

$6.07
+0.27  +5%
Phase 1/2 Phase 1/2 initiation of dosing announced July 28, 2021.
$458.3 million

MDWD – MediWound Ltd.
EscharEx
Venous leg ulcers (VLU’s)

$3.56
+0.06  +2%
Phase 2 Phase 2 trial to continue as planned as per Independent Data Monitoring Committee’s (IDMC) recommendation - July 28, 2021. Data due 1H 2022.
$97 million

MRSN – Mersana Therapeutics Inc.
Upifitamab rilsodotin (XMT-1536) - (UPGRADE)
Platinum-Sensitive Ovarian Cancer

$9.89
+0.18  +2%
Phase 1 Phase 1 initiation announced July 28, 2021.
$709.7 million

PFE – Pfizer Inc.
Comirnaty (BNT162b2)
COVID-19 vaccine

$43.89
-0.58  -1%
Approved FDA approval announced August 23, 2021.
$246.1 billion

RPHM – Reneo Pharmaceuticals Inc.
REN001 (STRIDE)
Primary mitochondrial myopathies (PMM)

$7.98
+0.22  +3%
Phase 2b Phase 2b commencement of dosing announced July 28, 2021. Data due in 2023.
$194.8 million

VNDA – Vanda Pharmaceuticals Inc.
Tradipitant
Gastroparesis

$16.95
+0.70  +4%
Phase 3 Phase 3 due by end of 2021.
$943.1 million

ZYME – Zymeworks Inc.
Zanidatamab and TUKYSA (Tucatinib)
HER2-positive breast cancer

$35.65
-0.45  -1%
Phase 1 Phase 1 initiation of dosing announced July 28, 2021.
$1.7 billion